A COMPARATIVE EVALUATION OF EFFECTIVENESS OF ACOTIAMIDE WITH RABEPRAZOLE VS MOSAPRIDE WITH RABEPRAZOLE IN PATIENTS WITH FUNCTIONAL DYSPEPSIA POST H.PYLORI ERADICATION

Background: Functional Dyspepsia is well dened when a patient had one or more of these symptoms with duration of three months or longer like post-prandial fullness, early satiation, epigastric pain and burning, bloating, nausea, vomiting and belching. Functional dyspepsia, consisting of epigastric pain syndrome and postprandial distress syndrome, is a prevalent functional gastrointestinal disorder. To date, only limited treatment options are available and conicting results in terms of efcacy have been reported. This was a prospective, com Methods: parative study carried out for a period of six months. Patient data were extracted from their medical records. Treatment outcome was evaluated based on the resolving of Symptoms using Gastrointestinal Symptom Rating Scale (GSRS), and (Hospital anxiety and depression scale) HADS scales. Descriptive statistics were used to summarize patient characteristics. Unpaired t-test and Mann Whitney test were used wherever appropriate. A total of 100 patients with conrmed funct Results: ional dyspepsia after H. pylori eradication were included.They were randomized into two study Groups namely Group 1 & 2. Each Group consists of 50 patients. Patients in Group 1 treated with Acotiamide and Rabeprazole. Group 2 patients treated with Mosapride and Rabeprazole. Patients with two different treatments have shown signicant improvement in gastrointestinal symptoms. The major risk factors are consumption of junk food, tea and spicy food. Our study shows that FD is predominant in Females than Males. Minor ADRS were reported which includes Nausea, Headache, dizziness and Constipation. study till date revealed that effects of both gastroprokinetic drugs help in enhancing Gastric emptying Rate (GER) , Gastric Accommodation Rate (GAR) and helps in acceleration of intestinal transit which ultimately results in preventing relaxation peristaltic movements respectively. Our study demonstrated that Mosapride and Acotiamide were both effective and well t Conclusion: olerated in FD patients without serious side effects. We found that effectiveness of Mosapride is 86% and Acotiamide is 84% thus Mosapride offers good alternative to Acotiamide in treating post H.pylori FD patients. Further investigations with increased sample are required in order to conrm the results in depth